New drug XKH004 shows promise in phase 3 trial for back pain from ankylosing spondylitis
NCT ID NCT07498634
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 3 trial tested a new drug called XKH004 in 323 adults with moderate-to-severe active ankylosing spondylitis, a type of arthritis that causes back pain and stiffness. The drug works by blocking two inflammatory proteins, IL-17A and IL-17F. Participants received either XKH004 or a placebo for 16 weeks, with the main goal being to see if more people on the drug achieved a 40% improvement in symptoms.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
XKH004 (an antibody that blocks IL-17A and IL-17F proteins to reduce inflammation)
What this could lead to
If successful, this could provide a new treatment option to control symptoms and slow disease progression in people with ankylosing spondylitis.
What could go wrong
This is a Phase 3 trial, but results are not yet published. The drug may not work better than placebo, and side effects like infections or allergic reactions are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANKYLOSING SPONDYLITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shanghai Changzheng Hospital
Shanghai, China